02:30am Sunday 20 August 2017

Breakthrough Model Holds Promise for Treating Graves Disease

Chevy Chase, MD—Researchers have developed the first animal model simulating the eye complications associated with the thyroid condition Graves’ disease, a breakthrough that could pave the way for better treatments, according to a recent study accepted for publication in The Endocrine Society’s journal Endocrinology.

Graves’ disease is an autoimmune disorder that causes the body to produce antibodies that attack the thyroid gland. The condition causes the thyroid gland to become overactive and produce too much thyroid hormone. If left untreated, it can lead to heart failure or osteoporosis.

Graves’ disease is most common in women. About 1 percent of Caucasian women have autoimmune thyroid disease where the thyroid is either over- or underactive. Among those who have Graves’ disease, more than half develop eye complications, according to the study’s lead author, J. Paul Banga, PhD, of King’s College London School of Medicine in the United Kingdom. These complications include Graves’ orbitopathy, where swelling of tissue behind the eyes causes them to bulge outward. The condition can cause pain and lead to blindness.

“Current treatment options for eye complications associated with Graves’ disease are limited,” Banga said. “Better treatments are needed for Graves’ orbitopathy to reduce the risks of permanent disfigurement and social stigma. Having an animal model to test preventative treatments could lead to important advances that will ultimately benefit people with Graves’ disease.”

The condition is currently treated with steroids, which can cause undesirable side effects such as weight gain and osteoporosis.

Although researchers have developed animal models of Graves’ disease in the past, these models were challenging to replicate and none were able to simulate the eye problems seen in people with Graves’ disease.

To develop the new model, researchers injected mice with small circular, double-stranded DNA molecules called plasmids. Over the course of three months, scientists used electronic pulses to ensure the DNA molecules were absorbed into the cells of each mouse. Mice that underwent this procedure developed eye problems like those seen in human patients who have Graves’ disease, while the control group of mice did not develop these complications.

“The new animal model opens the door for scientists to conduct needed mechanistic studies and identify preventative therapies to minimize this painful and debilitating condition,” Banga said.

Other researchers working on the study include: S. Moshkelgosha of King’s College London School of Medicine; P-W. So and N. Deasy of King’s College London; and S. Diaz-Cano of King’s College Hospital NHS Trust in London.

The article, “Retrobulbar Inflammation, Adipogenesis and Acute Orbital Congestion in a Preclinical Female Mouse Model of Graves’ Orbitopathy Induced by Thyrotropin Receptor Plasmid-in Vivo Electroporation,” will be published in the September issue of Endocrinology.

# # #

Founded in 1916, The Endocrine Society is the world’s oldest, largest and most active organization devoted to research on hormones and the clinical practice of endocrinology.  Today, The Endocrine Society’s membership consists of over 16,000 scientists, physicians, educators, nurses and students in more than 100 countries. Society members represent all basic, applied and clinical interests in endocrinology. The Endocrine Society is based in Chevy Chase, Maryland. To learn more about the Society and the field of endocrinology, visit our site at www.endocrine.org.

Contact: Aaron Lohr
Director, Media Relations
Phone: 240.482.1380
alohr@endocrine.org Contact: Jenni Glenn Gingery
Manager, Media Relations
Phone: 301.941.0240
jgingery@endocrine.org


Share on:
or:

MORE FROM Medical Breakthroughs

Health news